The present disclosure provides monoclonal antibodies against protein programmed cell death 1 ligand (PD-L1), which can block the binding of PD-L1to PD-1, and therefore block the inhibitory function of PD-L1 on PD-1 expressing T cells. The antibodies of disclosure provide very potent agents for the treatment of multiple cancers via modulating human immune function.

1. cd274 antibody
• The present disclosure provides monoclonal antibodies against
protein programmed cell death 1 ligand (PD-L1), which can block the
binding of PD-L1to PD-1, and therefore block the inhibitory function
of PD-L1 on PD-1 expressing T cells. The antibodies of disclosure
provide very potent agents for the treatment of multiple cancers via
modulating human immune function.

2. • ImmunogenHuman PD-L1 ECD protein
• Host SpeciesHuman
• TypeHuman Fab
• SpecificityHuman CD274
• Species ReactivityHuman, Cynomolgus, Mouse
• Clone1.14.4
• ApplicationsELISA, Flow Cytometry, Blocking, Functional Assay *
• Related DiseaseCancer

3. • Alternative NamesB7-H; B7H1; PDL1; PD-L1; PDCD1L1; PDCD1LG1
• Gene ID29126
• UniProt IDQ9NZQ7
• For research use only. Not intended for any clinical use. No products
from Creative Biolabs may be resold, modified for resale or used to
manufacture commercial products without prior written approval
from Creative Biolabs.